Article

Final Rule on Meaningful Use Offers More Flexibility for Docs

The final rule on the definition and requirements for demonstrating meaningful use of EHRs to qualify for federal incentives has been issued, and for doctors, it means more flexibility.

Healthcare professionals voiced their concerns, and rule makers listened.

At 10 a.m. EST this morning, the Office of the National Coordinator for Health Information Technology (ONC) issued a final rule on the definition and requirements for demonstrating meaningful use of EHRs to qualify for incentive payments under the HITECH Act.

The final regulations include several medications designed to provide more flexibility and multiple pathways for those charged with meeting meaningful use requirements. The changes, said David Blumenthal, MD, the National Coordinator for Health IT, were made in response to the 2,000-plus comments that were received in regard to the proposed rule, which was issued in December of 2009.

In particular, it was “concerns about the pace and scope of implementation of meaningful use” that led rule makers to “adopt a two-track approach regarding the objectives that allow practices and hospitals to qualify for incentive payments in the first 2 years of the program,” wrote Blumenthal and Marilyn Tavenner, RN, in an article published today in the New England Journal of Medicine.

The final rule outlines the specific criteria that must be met to achieve stage 1 meaningful use, and the clinical quality measure reporting requirements needed to receive incentive payments in 2011 and 2012 (the 864-page document is available here through the Office of the Federal Register).

The most notable changes to the proposed rule include the following:

• The number of quality measures that has to be met has been reduced to 44 (physicians must meet six of those objectives, and hospitals must meet 15)

• The number of measures required to demonstrate that EHRs are being used in a meaningful way has been reduced to 15 for physicians and 14 for hospitals

• The number of clinical decision support requirements has been reduced from five to one (for stage 1)

• The percentage of prescriptions that need to be sent electronically has decreased from 75% to 40%

In addition, some of the meaningful use quality reporting measures are being deferred to stage 2.

“The rule was too inflexible,” said Blumenthal during the press conference. Visit HCPLive.com later today and in the weeks ahead for more information on the final rule.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.